相似文献
1
A prospective study of autoantibodies to Ezrin and pancreatic cancer risk.
Cancer Causes Control. 2016 Jun;27(6):831-5. doi: 10.1007/s10552-016-0757-y. Epub 2016 May 4.
2
No evidence of pancreatic ductal adenocarcinoma specific autoantibodies to Ezrin in a liquid phase LIPS immunoassay.
Cancer Biomark. 2018;22(2):351-357. doi: 10.3233/CBM-181218.
3
Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models.
J Hematol Oncol. 2013 Sep 6;6:67. doi: 10.1186/1756-8722-6-67.
4
Diagnostic Value of Autoantibodies against Ezrin in Esophageal Squamous Cell Carcinoma.
Dis Markers. 2017;2017:2534648. doi: 10.1155/2017/2534648. Epub 2017 Feb 16.
5
Ezrin interacts with cortactin to form podosomal rosettes in pancreatic cancer cells.
Gut. 2009 Feb;58(2):271-84. doi: 10.1136/gut.2008.159871. Epub 2008 Oct 13.
6
Immunodiagnostic value of combined detection of autoantibodies to tumor-associated antigens as biomarkers in pancreatic cancer.
Scand J Immunol. 2012 Mar;75(3):342-9. doi: 10.1111/j.1365-3083.2011.02657.x.
7
Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Exp Mol Pathol. 2015 Feb;98(1):1-6. doi: 10.1016/j.yexmp.2014.11.003. Epub 2014 Nov 5.
8
A systematic review of serum autoantibodies as biomarkers for pancreatic cancer detection.
Oncotarget. 2016 Mar 8;7(10):11151-64. doi: 10.18632/oncotarget.7098.
9
Autoantibodies against tumor-associated antigens in the early detection of lung cancer.
Lung Cancer. 2016 Sep;99:172-9. doi: 10.1016/j.lungcan.2016.07.018. Epub 2016 Jul 18.
10
Prevalence and clinical significance of anti-laminin 332 autoantibodies detected by a novel enzyme-linked immunosorbent assay in mucous membrane pemphigoid.
JAMA Dermatol. 2013 May;149(5):533-40. doi: 10.1001/jamadermatol.2013.1434.
引用本文的文献
1
The Role of Circulating Protein and Metabolite Biomarkers in the Development of Pancreatic Ductal Adenocarcinoma (PDAC): A Systematic Review and Meta-analysis.
Cancer Epidemiol Biomarkers Prev. 2022 May 4;31(5):1090-1102. doi: 10.1158/1055-9965.EPI-21-0616.
2
Detecting the location and significance of Ezrin protein expression in hepatocellular carcinoma.
Int J Clin Exp Pathol. 2018 Jan 1;11(1):248-254. eCollection 2018.
本文引用的文献
1
A systematic review of serum autoantibodies as biomarkers for pancreatic cancer detection.
Oncotarget. 2016 Mar 8;7(10):11151-64. doi: 10.18632/oncotarget.7098.
2
Prognostic Value of Ezrin in Various Cancers: A Systematic Review and Updated Meta-analysis.
Sci Rep. 2015 Dec 3;5:17903. doi: 10.1038/srep17903.
3
Cancer statistics, 2015.
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5.
4
Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Exp Mol Pathol. 2015 Feb;98(1):1-6. doi: 10.1016/j.yexmp.2014.11.003. Epub 2014 Nov 5.
5
ERM proteins in cancer progression.
J Cell Sci. 2014 Jan 15;127(Pt 2):267-75. doi: 10.1242/jcs.133108.
6
Serologic autoantibodies as diagnostic cancer biomarkers--a review.
Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2161-81. doi: 10.1158/1055-9965.EPI-13-0621. Epub 2013 Sep 20.
7
Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models.
J Hematol Oncol. 2013 Sep 6;6:67. doi: 10.1186/1756-8722-6-67.
8
Ezrin promotes invasion and metastasis of pancreatic cancer cells.
J Transl Med. 2010 Jun 23;8:61. doi: 10.1186/1479-5876-8-61.
9
The Southern Community Cohort Study: investigating health disparities.
J Health Care Poor Underserved. 2010 Feb;21(1 Suppl):26-37. doi: 10.1353/hpu.0.0245.
10
Southern community cohort study: establishing a cohort to investigate health disparities.
J Natl Med Assoc. 2005 Jul;97(7):972-9.
Zotero 插件